Biotech News
Related news
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
ABOSAcumen Pharmaceuticals2026-08-12 11:00 EST
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
TNXPTonix Pharmaceuticals2026-08-10 11:00 EST
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
ADXNAddex Therapeutics2026-06-22 05:00 EST
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST
Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026
TSHATaysha Gene Therapies2026-08-04 20:00 EST
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
TNXPTonix Pharmaceuticals2026-07-27 11:00 EST
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
ECORelectroCore2026-07-30 12:00 EST
electroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026
NBIXNeurocrine Biosciences2026-07-09 20:01 EST
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
SUPNSupernus2026-07-14 12:30 EST
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
SUPNSupernus2026-05-27 20:30 EST
Supernus Pharmaceuticals to Participate in June Investor Conferences
Stock data
- Close
- 45.85 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States